Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
Enhancer of zeste homolog 2-mediated (EZH2-mediated) epigenetic regulation of T cell differentiation and Treg function has been described previously; however, the role of EZH2 in T cell-mediated antitumor immunity, especially in the context of immune checkpoint therapy, is not understood. Here, we showed that genetic depletion of EZH2 in Tregs (FoxP3creEZH2fl/fl mice) leads to robust antitumor immunity. In addition, pharmacological inhibition of EZH2 in human T cells using CPI-1205 elicited phenotypic and functional alterations of the Tregs and enhanced cytotoxic activity of Teffs. We observed that ipilimumab (anti-CTLA-4) increased EZH2 expression in peripheral T cells from treated patients. We hypothesized that inhibition of EZH2 expression in T cells would increase the effectiveness of anti-CTLA-4 therapy, which we tested in murine models. Collectively, our data demonstrated that modulating EZH2 expression in T cells can improve antitumor responses elicited by anti-CTLA-4 therapy, which provides a strong rationale for a combination trial of CPI-1205 plus ipilimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“The combination of EZH2 inhibition with anti-CTLA4 therapy led to improved survival in the preclinical studies (116).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“On the basis of these observations, a series of preclinical studies were designed that identified a potential role for EZH2 in driving adaptive resistance to anti-CTLA4 therapy.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundZhou, X., Bailey-Bucktrout, S. L., Jeker, L. T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1774 · Cited by 1,370 · cited 1×
“CPI-1205–treated Tregs seem to acquire the phenotype of so-called exFoxP3 cells, which were previously shown to have an activated memory phenotype (19).”
BackgroundEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“As EZH2 regulates expression of Th-1 chemokines such as CXCL9 and CXCL10 in the tumor cells (14), we performed in vitro (cell line) and in vivo (murine tumor model) experiments to assess the contribution of CXCL9 and CXCL10 in our system.”
MethodWei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
Delgoffe, G. M., Woo, S.-R., Turnis, M. E., Gravano, D. M., Guy, C., Overacre, A. E., Bettini, M. L., Vogel, P., Finkelstein, D., Bonnevier, J., et al. (2013) · Nature · doi:10.1038/nature12428 · Cited by 587
BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis
Roychoudhuri, R., Hirahara, K., Mousavi, K., Clever, D., Klebanoff, C. A., Bonelli, M., Sciumè, G., Zare, H., Vahedi, G., Dema, B., et al. (2013) · Nature · doi:10.1038/nature12199 · Cited by 407
Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K., & O'Shea, J. J. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075058 · Cited by 342
DuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332 · cited 2×
“org Volume 128 Number 9 September 2018 Introduction Enhancer of zeste homolog 2 (EZH2) is expressed in T cells following its activation via CD28 signaling (1).”
Background
Cited by
Items 201–245 of 245
Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy
Zheng, R., Zhu, X., & Xiao, Y. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04046-9 · Cited by 3
“Additionally, EZH2 plays a key regulatory role in T cells, modulating anti-tumor immune responses [75].”
Beadnell, T. C., Borriello, L., Christenson, J. L., Fornetti, J., Guldner, I. H., Hanna, A., Kyjacová, L., Whately, K. M., Martins, P. C. D. M., Rotinen, M., et al. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-09953-y · Cited by 2
Epigenetic enhancement of adoptive T cell immunotherapy
Dai, Z., & Smith, M. M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.022 · Cited by 1
Hjazi, A. M., Hussn, A., Kareem, A. K., Alshahrani, M. Y., Malathi, H., Nayak, P. P., Chauhan, A. S., & Sharma, J. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114648 · Cited by 2
Stoyanova, T. I., Priceman, S. J., Ross, A. E., Tran, P. T., McKay, R. R., Pienta, K. J., Soule, H. R., & Miyahira, A. K. (2025) · The Prostate · doi:10.1002/pros.70102 · Cited by 1
“Earlier studies by Goswami and colleagues found that EZH2 inhibition increases CD8 T cells inside prostate tumors and attenuates Tregs, with EZH2 inhibition improving responses to anti ‐ CTLA4 ICB in mouse models [117].”
Yan, Q., Qingqing, Z., Yu, S., & Zhang, W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2598380 · Cited by 3
“This epigenetic rewiring potentiates anti-CTlA-4 therapy by improving CD8 + and CD4 + effector T cell recruitment and function, and altering the TME to efficiently eradicate malignancies [167,168].”
Niu, S., Liu, C., & Deng, Q. (2026) · Cell Transplantation · doi:10.1177/09636897261449351 · Cited by 1
“For instance, EZH2 inhibitors can reverse MHC expression defects and restore antigen-presenting function, thereby enhancing the tumor-recogni-tion capacity of ICIs or CAR-T cells—a strategy that has been established as an important therapeutic target for improving immune recognition 72 .”
Tan, J., Wen, T., Liu, J. S., & Ru, X. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01828-0 · Cited by 2
Epigenetic priming—fact or falacy?
Revuelta, M. V., & Cerchietti, L. C. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00009-x · Cited by 1
Evolution of Biomarkers and Treatment Outcomes of Immunotherapy in Lung Cancer
Kaler, A. K., Maskomani, S., Ritambhara, Kavyashree, K., Vadera, V., Choudhary, V., Shaikh, I. N., Goyle, S., & Mistry, R. (2023) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-023-00047-w · Cited by 1
“Inhibiting EZH2 has shown to enhance the response to anti-CTLA-4 therapy [106, 107].”
Arabpour, J., Davodabadi, F., & Nigam, M. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_3 · Cited by 1
Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1
Peeters, J. G. C., Silveria, S. L., Özdemir, M., Ramachandran, S., & DuPage, M. J. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.05.588284 · Cited by 1
L’actualité immunologique sous l’oeil critique des étudiants de Master 2
Achari, Y., Ali, F., Boudache, A., Bui-Xuan, P., Furge, P., Labatte, J., & Stanciu, R. (2019) · médecine/sciences · doi:10.1051/medsci/2019070
The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy
Wen, S., Wang, H., & Lu, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823684-0.00013-x · Cited by 1
Ma, X. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738784119.793583429
Sharma, P., Anandhan, S., Siddiqui, B. A., Goswami, S., Subudhi, S. K., Gao, J., Peggs, K. S., Quezada, S. A., & Allison, J. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068.pub2
Schlom, J., Gameiro, S. R., Palena, C., & Gulley, J. L. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm066.pub2
Future Prospects for Targeting the Epigenome in Lymphomas
Isshiki, Y., & Melnick, A. M. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch17
Epigenetic therapy in lung cancer
Conroy, M. R., O’Connor, Á., Bailey‐Whyte, M., & Dowling, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00004-0
Single cell suppression profiling of human regulatory T cellsPreprint
Søndergaard, J. N., Tulyeu, J., Priest, D., Sakaguchi, S., & Wing, J. B. (2024) · Research Square · doi:10.21203/rs.3.rs-4327429/v1
Epigenetische Therapien in der Krebsbehandlung: Chancen und Herausforderungen
Heßmann, E., & Schneider, G. (2025) · Forum · doi:10.1007/s12312-024-01411-z
“In präklinischen Tumormodellen verschiedener Entitäten wurden durch die gemeinsameApplikationvonEZH2-Inhibi-toren und immunmodulatorischen Medi-kamentenwiedenCheckpoint-Inhibitoren Anti-PD-L1/PD-1 [52–54]oder CTLA-4 [55] ermutigende Ergebnisse erzielt.”
Regulatory T Cells in Tumor Immunity
Kang, J. H., Nagarsheth, N., Kryczek, I., Wei, S., Frankel, T. L., Zou, W., & Zappasodi, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00201-5
EZH2 Inhibition Boosts Tumor Immunogenicity and TIL Reactivity in Lung CancerPreprint
Plaugher, D. R., Gosser, C. M., Lin, Y., Childress, A. R., Liu, J., Liu, J., Qu, X., DuCote, T. J., Esoe, D.-P. I., Gandhapudi, S. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.12.663845
“However, other studies have shown that EZH2 deletion can reprogram regulatory T cells (T R ) to T-effector cells (T EFF ), and lead to de-repression of transcription factors Tcf7 and Id3 important for memory T cells (T M ) (10, 12-14) .”
Shi, M.-X., Ding, X., Tang, L., Cao, W.-J., Su, B., & Zhang, J. (2024) · Figshare · doi:10.6084/m9.figshare.26709632
Ye, Y., Kuang, X., Xie, Z., Liang, L., Zhang, Z., Zhang, Y., Ma, F., Gao, Q., Chang, R., Lee, H.-H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13018227
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Figshare · doi:10.6084/m9.figshare.14299486
Zhao, H., Liu, H., Kang, W., Zhan, C., Man, Y., & Qu, T. (2024) · Figshare · doi:10.6084/m9.figshare.26612819
Zhang, H., Huang, C., Gordon, J., Yu, S., Morton, G. C., Childers, W., Abou-Gharbia, M., Zhang, Y., Jelínek, J., & Issa, J.-P. J. (2024) · Figshare · doi:10.6084/m9.figshare.24940680
Zhao, H., Liu, H., Kang, W., Zhan, C., Man, Y., & Qu, T. (2024) · Figshare · doi:10.6084/m9.figshare.26612816
Tumor microenvironment-induced epigenetic reprogramming of Tregs and its impact on immunotherapy
Li, W., & Tong, J. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1787421
“Moreover, hypoxia-driven upregulation of EZH2 in the TME facilitates the deposition of H3K27me3 across the genome, leading to the suppression of genes associated with Treg differentiation and function (Goswami et al., 2018).”
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Cao, M., Zhou, N., Wang, C., Xu, Y., Li, X., Sui, L., Wang, Y., Wang, Y., & Yang, X. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04573-1
Hao, Z., Villano, J. L., Arnold, S. M., & Anthony, L. B. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261458324
Zhou, H., Lin, H., Kong, Y., Pan, H., Chai, W., Sun, L., Wang, Y., Ge, M., Ji, X., Yao, R., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09003-6 · Cited by 1
“The EZH2 small-molecule inhibitor CPI-205 has been reported to enhance the antitumor effect of CTLA-4 blockade [5].”
Wang, M., Wang, L., & Yuan, J. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117143
Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies
Tetens, A. R., Craig-Schwartz, J., Findlay, T., & Koldobskiy, M. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1857121
“Co-culture of the leukemia cell line, NALM6, with naive CD4+ and CD8+ T cells in the presence of a bispeci fi c T-cell engager (BiTE) increases target cell lysis at lower effector-to-target cell ratios when cultured in the presence of an EZH2i (173).”
InfluentialEpigenetic-targeted nanomedicine in cancer: from molecular mechanisms to therapeutic revolution
Wang, B., Han, Y., Zhang, X., Li, Y., Cai, Z., Duan, Z., Gong, Q. H., Jiang, Y., & Luo, K. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101789
Nisimoto, M. Y. S. M., de Oliveira, D. A., Bottura, H. R., Sousa, W. R. G., Sividanes, G. D. N., Marques, A. F., Hunnicutt, J. M. S., Romagnolo, A. G., Vivi, M. C. F., Gorini, B. L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879451
“EZH2 is required for the maintenance of stem-like and memory CD8 + T-cell populations, which are critical for durable anti-tumor immunity and sustained responses to immune checkpoint blockade and adoptive cell therapies (Goswami et al., 2018; Hou et al., 2025).”
Development of EZH2-based combination therapies and dual-target inhibitors for antitumor effects
Ma, Y., Zhang, Q., & Zhou, X. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110640
Bai, Y., Chen, H., & Gu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1909464
BindingDB (2023) · UC San Diego · doi:10.7270/q2pr80z0
Gallardo‐Gómez, M., Termenón-Rivas, U., Alonso-Álvarez, I., Lázaro-Quintela, M., Aversa, C., Fernández, A. F., Rodríguez-Rodríguez, M., Brea, J., Abdulkader-Sande, S., Rodríguez‐Casanova, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015745
Metadata
- Authors
- Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., Allison, J. P., Zhao, H., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Constellation Pharmaceuticals (United States) (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-30
- Volume
- 128
- Issue
- 9
- Pages
- 3813-3818
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6118570
- OpenAlex
- W2807710457
- Cited by
- 244
- References
- 22
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 25 · 2022: 28 · 2021: 46 · 2020: 41 · 2019: 21 · 2018: 2
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy, National Institutes of Health (R01CA163793)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- EZH2, epigenetic regulation, CTLA-4, ipilimumab, CTLA-4 blockade, regulatory T cells, Foxp3, EZH2 inhibition, antitumor immunity, T cell immunity, combination immunotherapy, tumor immunology
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Immunological, Ipilimumab, Animals, Enzyme Inhibitors, Humans, Indoles, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Piperidines, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.